The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy chinese male subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1620-1627

  Jiang, Ji ^a   Zhang, Jianyan ^a   Jacobsen, Lisbeth V ^b   Hu, Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NOVO NORDISK A S   (Denmark)

Author keywords

GLP 1 analogue; liraglutide; pharmacodynamics; pharmacokinetics; tolerability

Indexed keywords

GLUCOSE; INSULIN; LIRAGLUTIDE; PLACEBO;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIARRHEA; DOUBLE-BLIND METHOD; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; NAUSEA; YOUNG ADULT;

EID: 82955194834     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010389468     Document Type: Article

References (33)

1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995 ; 44: 1249-1258
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 ; 29: 46-52 (Pubitemid 16162741)
3. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 ; 30: 753-759 (Pubitemid 46354366)
4. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996 ; 39: 1546-1553 (Pubitemid 26397366)
5. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003 ; 52: 380-386 (Pubitemid 36173193)
6. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev. 2003 ; 19: 115-123 (Pubitemid 36417195)
7. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol. 2005 ; 23: 857-861
8. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 ; 101: 515-520 (Pubitemid 28084232)
9. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001 ; 24: 1416-1421 (Pubitemid 33716430)
10. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide- 1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999 ; 140: 5356-5363
11. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007 ; 16: 231-237 (Pubitemid 46206637)
12. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily administration. J Med Chem. 2000 ; 43: 1664-1669 (Pubitemid 30304999)
13. Russell-Jones D. Molecular, pharmacological, and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009 ; 297: 137-140
14. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 ; 45: 195-202 (Pubitemid 34208381)
15. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 ; 53: 1187-1194 (Pubitemid 38569002)
16. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002 ; 25: 1398-1404 (Pubitemid 41071152)
17. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006 ; 46: 635-641
18. Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther. 2008 ; 46: 273-279 (Pubitemid 351890729)
19. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009 ; 373: 473-481
20. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009 ; 26: 268-278
21. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomized controlled trial. Diabetologia. 2009 ; 52: 2046-2055
22. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009 ; 32: 1224-1230
23. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008 ; 25: 152-156 (Pubitemid 351293400)
24. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Presented at: 59th WMA General Assembly ; Seoul, Korea ;..
25. Good clinical practice. Presented at: International Conference on Harmonisation Steering Committee meeting ; Virginia, USA ;..
26. EPARs for authorized medicinal products for human use. Annex I-summary of product characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/001026/human-med-001137.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true. Accessed date January 13, 2011.
27. Kageyama S, Hirao K, Shimizu A, et al. Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue-phase 1 studies in Japanese healthy subjects with type 2 diabetes. Endocrinol DiabetoL. 2007 ; 24: 95-104
28. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008 ; 81: 161-168
29. Gutniak MK, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care. 1994 ; 17: 1039-1044 (Pubitemid 24268617)
30. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993 ; 36: 741-744 (Pubitemid 23218642)
31. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002 ; 51: 424-429 (Pubitemid 34764798)
32. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia. 1995 ; 38: 720-725
33. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 ; 368: 1696-1705 (Pubitemid 46048557)